Varizig approved to reduce chickenpox symptoms

December 22, 2012
Varizig approved to reduce chickenpox symptoms
Varizig (varicella zoster immune globulin) has been approved by the U.S. Food and Drug Administration to minimize chickenpox symptoms when administered within four days of exposure to the virus that causes the disease.

(HealthDay)—Varizig (varicella zoster immune globulin) has been approved by the U.S. Food and Drug Administration to minimize chickenpox symptoms when administered within four days of exposure to the virus that causes the disease.

Varizig was approved for high-risk people, including those with compromised immune systems, newborns, pregnant women, , children less than a year old, and people with no immunity to the virus, the FDA said Friday in a news release.

Varizig is produced from the of healthy donors with high levels of antibodies to the chicken-pox-causing virus, the FDA said. The donated plasma comes from collection facilities licensed by the FDA.

The drug is meant to be administered in one or more doses, depending on the recipient's weight, within 96 hours of exposure. The most common side effects noted in clinical testing were injection-site pain and headache.

Varizig is produced by Cangene Corp., based in Winnipeg, Canada.

Explore further: Generic boniva approved for osteoporosis

More information: More Information

Related Stories

Generic boniva approved for osteoporosis

March 19, 2012

(HealthDay) -- The first generic versions of the once-monthly osteoporosis drug Boniva (ibandronate) have been approved by the U.S. Food and Drug Administration.

New drug approved for lack of certain white blood cells

August 30, 2012

(HealthDay)—The U.S. Food and Drug Administration has approved the drug tbo-filgrastim to treat certain cancer patients undergoing chemotherapy who have a condition called severe neutropenia, the FDA said in a news release.

Xeljanz approved for rheumatoid arthritis

November 7, 2012

(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.